These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9533 related articles for article (PubMed ID: 15696607)

  • 1. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1).
    Kohlgraf KG; Gawron AJ; Higashi M; VanLith ML; Shen X; Caffrey TC; Anderson JM; Hollingsworth MA
    Cancer Immunol Immunother; 2004 Dec; 53(12):1068-84. PubMed ID: 15696607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of organ site and tumor cell type on MUC1-specific tumor immunity.
    Morikane K; Tempero R; Sivinski CL; Kitajima S; Gendler SJ; Hollingsworth MA
    Int Immunol; 2001 Feb; 13(2):233-40. PubMed ID: 11157856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice.
    Tempero RM; VanLith ML; Morikane K; Rowse GJ; Gendler SJ; Hollingsworth MA
    J Immunol; 1998 Nov; 161(10):5500-6. PubMed ID: 9820526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
    Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
    Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
    Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
    Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain.
    Plunkett T; Graham R; Correa I; Sewell R; Miles D; Burchell J; Taylor-Papadimitriou J
    Int J Cancer; 2004 May; 109(5):691-7. PubMed ID: 14999776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
    Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.
    Ryan SO; Turner MS; Gariépy J; Finn OJ
    Cancer Res; 2010 Jul; 70(14):5788-96. PubMed ID: 20587526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
    Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
    Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.
    Wu X; Yin Z; McKay C; Pett C; Yu J; Schorlemer M; Gohl T; Sungsuwan S; Ramadan S; Baniel C; Allmon A; Das R; Westerlind U; Finn MG; Huang X
    J Am Chem Soc; 2018 Dec; 140(48):16596-16609. PubMed ID: 30398345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses.
    VanLith ML; Kohlgraf KG; Sivinski CL; Tempero RM; Hollingsworth MA
    Int Immunol; 2002 Aug; 14(8):873-82. PubMed ID: 12147624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice.
    Heukamp LC; van der Burg SH; Drijfhout JW; Melief CJ; Taylor-Papadimitriou J; Offringa R
    Int J Cancer; 2001 Feb; 91(3):385-92. PubMed ID: 11169964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.
    Rowse GJ; Tempero RM; VanLith ML; Hollingsworth MA; Gendler SJ
    Cancer Res; 1998 Jan; 58(2):315-21. PubMed ID: 9443411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice.
    Tempero RM; Rowse GJ; Gendler SJ; Hollingsworth MA
    Int J Cancer; 1999 Feb; 80(4):595-9. PubMed ID: 9935162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine.
    Rong Y; Jin D; Wu W; Lou W; Wang D; Kuang T; Ni X; Qin X
    BMC Cancer; 2009 Jun; 9():191. PubMed ID: 19534821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
    Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; Livingston PO; Hilgers J; Kenemans P
    Int J Cancer; 2001 Jul; 93(1):97-106. PubMed ID: 11391628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.
    Gong J; Apostolopoulos V; Chen D; Chen H; Koido S; Gendler SJ; McKenzie IF; Kufe D
    Immunology; 2000 Nov; 101(3):316-24. PubMed ID: 11106934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1.Tg mice.
    Pinkhasov J; Alvarez ML; Rigano MM; Piensook K; Larios D; Pabst M; Grass J; Mukherjee P; Gendler SJ; Walmsley AM; Mason HS
    Plant Biotechnol J; 2011 Dec; 9(9):991-1001. PubMed ID: 21740504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
    Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
    Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 477.